Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy
← catalyst calendarSponsored by BioNTech SE (industry) · BNTX — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
2,079actual
Sites
74
Countries
Belgium, Germany, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-07-02 | actual | When the study began enrolling |
| Primary completion | 2025-04-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-23 | actual | The whole study's end, after follow-up |
| First posted | 2021-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Colorectal Cancer Stage II
- Colorectal Cancer Stage III
Intervention
- Procedure: Regular blood sample collection for ctDNA assessment
Primary outcome
what the primary-completion date above is the date OFOccurrence of ctDNA positivity in the post-surgery/pre-AdCTx blood sample
measured 4 to 8 weeks (28 to 56 days) after surgery and within 7 days prior to start of AdCTx
Permalink · BNTX's whole pipeline · Catalyst calendar · Every registered study · What changed